CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

The goal of this prospective, multicentric, single-arm, phase I/II clinical trial is to evaluate the safety and efficacy of a novel CD19-directed CAR-T cell locally produced in an academic institution in Brazil in patients with refractory or relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants will receive a single intravenous infusion of an autologous academic anti-CD19 CAR-T cell and will be followed for 5 years.

Trial Details

NCT ID
NCT06101381
Phase
PHASE1 / PHASE2
Sponsor
University of Sao Paulo
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • CART-19
Locations (sample)
  • Campinas, São Paulo, Brazil|-22.90556,-47.06083
  • Ribeirão Preto, São Paulo, Brazil|-21.1775,-47.81028
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611

Key Eligibility Criteria

  • For non-Hodgkin Lymphomas (B-NHL):
  • Provision of signed Informed Consent form;
  • Age between 18 and 70 years;
  • Performance status according to the Eastern Cooperative Oncology Group \< 2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →